Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Received | |||
Repatha | evolocumab | Primary hyperlipidemia | Active | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
Jemperli | dostarlimab | Endometrial cancer | Active | |||
Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Active | |||
Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
Remsima | infliximab | Crohn’s disease | Active |